Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone

被引:11
|
作者
Palomba, S [1 ]
Morelli, M [1 ]
Di Carlo, C [1 ]
Noia, R [1 ]
Pellicano, M [1 ]
Zullo, F [1 ]
机构
[1] Univ Catanzaro, Dept Obstet & Gynecol, Chair Obstet & Gynecol, Catanzaro, Italy
关键词
GnRH-a; tibolone; bone loss; BMD; postmenopause; analog; leiomyoma;
D O I
10.1016/S0015-0282(02)03149-7
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To study the bone metabolism in postmenopausal women who have been treated with gonadotropin-releasing hormone agonist (GnRH-a) and tibolone. Design: Prospective, open. controlled clinical trial. Setting: Department of Gynecology and Obstetrics, University of Catanzaro, Catanzaro, Italy. Patient(s): One hundred twenty perimenopausal women with symptomatic uterine leiomyomas (groups A and 13), and 40 healthy control women who underwent a normal spontaneous menopause (group C). Intervention(s): Treatment for 12 months with leuprolide acetate plus tibolone (group A) or hysterectomy with bilateral oophorectomy (group B). Main Outcome Measure(s): Lumbar spine bone mineral density (BMD) and bone turnover markers at entry into the study, after medical treatment (only group A), and 12 months after discontinuation medical treatment (group A) or after surgery (group 13). The same parameters were noted in healthy women before and 12 months after menopause (retrospective control group, group C). Result(s): At the women's entry into the study, no significant difference in BMD and bone turnover markers was detected between groups A and B. In group A. no significant variation in BMD or bone turnover markers was observed 12 months after medical treatment in comparison with baseline. At 12 months after discontinuation of treatment (in women who had achieved menopause) and after surgery, we observed a statistically significant decrease in BMD and in bone turnover markers in both groups in comparison with baseline. At 12 months after they became menopausal, we also observed a statistically significant reduction in BMD and in bone turnover markers in control group C. At the same 12-month follow-up visit, a statistically significant difference in BMD and in bone turnover markers was detected when comparing groups A and B with group C. Conclusion(s): Women previously treated with GnRH-a and tibolone similar to women who are menopausal as a result of surgery, have higher bone loss after menopause. (C) 2002 by American Society for Reproductive Medicine.
引用
收藏
页码:63 / 68
页数:6
相关论文
共 50 条
  • [21] Gonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls
    Arani, Kobra Shiasi
    Heidari, Fatemeh
    [J]. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2015, 13 (03)
  • [22] Metachromasia of the endocervical epithelium in women treated with gonadotropin releasing hormone agonist
    Morimura, M
    Ishiko, O
    Honda, K
    Sumi, T
    Kawamura, N
    Wakasa, K
    Haba, T
    Ogita, S
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2001, 8 (03) : 319 - 321
  • [23] INTRANASAL GONADOTROPIN-RELEASING HORMONE AGONIST AS A CONTRACEPTIVE AGENT
    BERGQUIST, C
    NILLIUS, SJ
    WIDE, L
    [J]. LANCET, 1979, 2 (8136): : 215 - 217
  • [24] GONADOTROPIN-RELEASING HORMONE AGONIST TREATMENT OF ENDOMETRIOSIS AND MYOMAS
    GIUDICE, LC
    [J]. WESTERN JOURNAL OF MEDICINE, 1990, 152 (04): : 409 - 409
  • [25] Utilization of gonadotropin-releasing hormone agonist products in adolescents
    Woods, Corinne
    Ho, Amy
    Dutcher, Sarah K.
    Ajao, Adebola
    Hawrusik, Rebecca
    Schoeplein, Ryan
    Moeny, David
    Huang, Ting-Ying
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 319 - 320
  • [26] ENDOMETRIOSIS - TREATMENT WITH GONADOTROPIN-RELEASING HORMONE AGONIST BUSERELIN
    FRANSSEN, AMHW
    KAUER, FM
    CHADHA, DR
    ZIJLSTRA, JA
    ROLLAND, R
    [J]. FERTILITY AND STERILITY, 1989, 51 (03) : 401 - 408
  • [27] Luteal phase support with gonadotropin-releasing hormone agonist
    Tsui, Kuan-Hao
    Lin, Li-Te
    Wang, Peng-Hui
    [J]. JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2014, 77 (10) : 505 - 507
  • [28] Prolonged use of gonadotropin-releasing hormone agonist and tibolone as add-back therapy for the treatment of endometrial hyperplasia
    Agorastos, T
    Vaitsi, V
    Paschopoulos, M
    Vakiani, A
    Zournatzi-Koiou, V
    Saravelos, H
    Kostopoulou, E
    Constantinidis, T
    Dinas, K
    Vavilis, D
    Lolis, D
    Bontis, JB
    [J]. MATURITAS, 2004, 48 (02) : 125 - 132
  • [29] CORTICAL AND TRABECULAR BONE-MINERAL CONTENT IN WOMEN WITH ENDOMETRIOSIS - EFFECT OF GONADOTROPIN-RELEASING HORMONE AGONIST AND DANAZOL
    DAWOOD, MY
    LEWIS, V
    RAMOS, J
    [J]. FERTILITY AND STERILITY, 1989, 52 (01) : 21 - 26
  • [30] Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study
    Bodri, Daniel
    Guillen, Juan Jose
    Galindo, Anna
    Mataro, Daniel
    Pujol, Aida
    Coll, Oriol
    [J]. FERTILITY AND STERILITY, 2009, 91 (02) : 365 - 371